Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 8/20 | 1.00 |
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.70 |
| ▸ | PLG | P00747 | 3/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.57 |
| ▸ | PLAT | P00750 | 2/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.56 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.49 |
| ▸ | F12 | P00748 | 1/20 | 0.47 |
| ▸ | HPN | P05981 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334508 | 0.88 | PLAU (0.78) | PLAUASIC3PLGKLKB1PRSS1 | |
| SCHEMBL7336373 | 0.83 | ASIC3 (0.77) | PLAUASIC3PLGKLKB1PRSS1 | |
| SCHEMBL7346595 | 0.79 | PLAU (0.64) | PLAUASIC3PLGKLKB1PRSS1 | |
| Trifluoroacetic Acid SCHEMBL7335751 | 0.79 | PLAU (0.80) | PLAUASIC3PLGKLKB1PRSS1 | |
| SCHEMBL7337416 | 0.76 | PLAU (0.60) | PLAUASIC3PLGKLKB1PRSS1 | |
| SCHEMBL7333152 | 0.76 | PLAU (0.70) | PLAUPLGKLKB1PRSS1PLAT | |
| SCHEMBL49594 | 0.74 | LOXL2 (1.00) | PLAUPLGKLKB1PRSS1PLAT | |
| SCHEMBL15902204 | 0.74 | ASIC3 (0.63) | PLAUASIC3PLGKLKB1PRSS1 | |
| Trifluoroacetic Acid SCHEMBL7335057 | 0.73 | ASIC3 (0.79) | PLAUASIC3PLGKLKB1PRSS1 | |
| SCHEMBL7334977 | 0.73 | PLAU (0.65) | PLAUASIC3PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | PLAU 2/4885ASIC3 4314/4885PLG 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.